Survival Disparities of Diffuse Large B-Cell Lymphoma (DLBCL) in a Community-Based Inner-City Cancer Center

There is persistent racial disparities in survival among patients with Diffuse Large B Cell Lymphoma. We conducted a cohort study of 181 patients for 10 years in a single community-based inner-city cancer center. Blacks had decreased overall survival compared to non-Blacks even after excluding patients with HIV and who did not receive chemotherapy. R-IPI score alone could not predict worse outcomes and increased mortality in Blacks with DLBCL.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

We hypothesized that higher Charlson comorbidity index(CCI) predicts worse one-month mortality and overall survival(OS) in patients ≥60 years with acute myeloid leukemia(AML). In our National Cancer Database study, patients with CCI 0 were more likely to receive chemotherapy and undergo upfront hematopoietic cell transplant. One-month mortality and OS were significantly worse with CCI 1 or ≥2, compared to CCI 0.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Improvements in cancer treatment and supportive care, as well as the approval of oral chemotherapy medications over the past decade, have resulted in an increasing number of cancer patients treated in outpatient settings. Transitioning cancer treatments outpatient places greater emphasis on medication counseling and side effect management. Literature demonstrates improvements in medication adherence and symptom management with the addition of an oncology pharmacist. Historically, the University of Chicago Medical Center (UCMC) has not employed pharmacists into their oncology clinics. As of August 2018, UCMC is evaluating p...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
ConclusionsIn the largest real-world study, we demonstrate an association between factors such as age, comorbidity and AML subtypes, and the use of multiagent chemotherapy. The use of multiagent chemotherapy was associated with improved OS, particularly among patients younger than 70 years, good-risk AML and those with low Charlson comorbidity score.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Kim De Veirman AXL belongs to the TAM (TYRO3, AXL, and MERTK) receptor family, a unique subfamily of the receptor tyrosine kinases. Their common ligand is growth arrest-specific protein 6 (GAS6). The GAS6/TAM signaling pathway regulates many important cell processes and plays an essential role in immunity, hemostasis, and erythropoiesis. In cancer, AXL overexpression and activation has been associated with cell proliferation, chemotherapy resistance, tumor angiogenesis, invasion, and metastasis; and has been correlated with a poor prognosis. In hematological malignancies, the expression and function of AXL is highly...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
CONCLUSION: All tested biosimilars demonstrated similar effectiveness and safety profiles in patients with hematological tumors undergoing PBSC mobilization; therefore, they can be used interchangeably. PMID: 31663634 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: J Clin Apher Source Type: research
Publication date: Available online 21 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Luo Huang, Yongzhong Wu, Ying Wang, Yue Xie, Furong Wu, Shujie Li, Zhongguo Liang, Xiaodong ZhuAbstractThe aim of this study is to develop a prognostic nomogram for early stage extranodal NK/T-cell lymphoma, nasal-type (ENKL) treated with high-dose radiotherapy (RT). A total of 81 patients at two cancer centers with stage I to IIE ENKL who received chemotherapy (CT) and high-dose RT were retrospectively analyzed. The 5-year OS rate and PFS were 64.7% and 57.5% respectively for the entire group. The development of the ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Post-transplant lenalidomide (L) maintenance (LM) is used routinely in frontline treatment of patients with multiple myeloma. However, it's impact on response to L-containing therapy in first relapse is unclear. This is of critical importance given the efficacy of L-containing therapy in relapsed disease. We sought to address this question using the Myeloma Canada Research Network Canadian Multiple Myeloma Database (MCRN CMM-DB), a centralized research platform encompassing data from 13 Canadian cancer centers.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
The OCM was introduced in 2016 with the goal of improving quality and reducing costs associated with cancer care. Under this framework, practices are incentivized to reduce spending on chemotherapy-centered episodes. A previous study using SEER-Medicare data (2007 –2013) suggested that reducing OCM episode costs in multiple myeloma (MM) may adversely affect patient survival. The present study aimed to evaluate the association between OCM-defined episode costs as well as MM-specific drug costs and overall survival (OS) in MM patients, using more recent data (2010–2015) and included 100% Medicare patients.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Patients with Multiple Myeloma (MM) are enjoying significant improvement in overall survival as the result of advent of novel anti-myeloma agent that replace traditional chemotherapy, in addition to the increased use of transplant. The prices of novel agents, especially oral ones, have been rapidly escalating and there are well-described issues with affordability (Shih et al. JCO 2017). We therefore hypothesized that insurance status influences MM patients (pts) survival. National Cancer Database (NCDB), covering 70% of MM patient nationwide was utilized.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Corticosteroids (steroids) play a central role in the treatment of MM and are widely recognised to cause a wide range of side effects that adversely impact health related quality of life (HRQoL). Patient reported outcome measures (PROMs) are tools that enable patients to report their health status and the presence and severity of symptoms. A range of PROMs are available to assess symptoms in MM but no such tool exists to measure the impact of steroids in this population. The Dexamethasone Symptom Questionnaire Chronic (DSQ-C) is an 18-item measure, initially developed to determine the incidence and severity of symptoms exp...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma | Study